ABOUT US
About Acoustic Cell Therapy, Inc.
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment based on the genetic engineering of patients’ T cells to destroy tumor cells. Despite its huge success in treating blood cancers, CAR-T cells can attack normal organs/tissues expressing similar target antigens (on-target off-tumor toxicity: OTOT), leading to potentially life-threatening consequences and patient death. There is hence an urgent need to control CAR-T cell actions with high precision in space and time. Ultrasound can be focused on the local regions of deep organs/tissues in the body to control cell genetics and functions. Acoustic Cell Therapy Inc. engineers ultrasound controllable genetics and cells that can be reversibly activated by short pulsed ultrasound (in minutes) at a local tumor area for cell based immunotherapy. This remote, noninvasive, reversible and local activation of genetics and cells by ultrasound can achieve a high level of efficiency and persistency, specificity and safety in killing solid tumors. Acoustic Cell Therapy Inc. has exclusive rights to this technology through a license from UC San Diego.
Meet the Team
-
Yingxiao (Peter) Wang
CHIEF CONSULTANT
Peter is a Professor of Bioengineering at University of California, San Diego. His research focused on the molecular engineering for cellular imaging and reprogramming.
-
Nina Xu
CEO
Nina obtained her master’s degree in global business from Technical University of Berlin. She has extensive experience in business management and production operations
-
Dulei Li
CTO
Dulei obtained her Ph.D. degree in immunology from Tsinghua University, with 9 years of experience in immunology, including innate lymphocytes, CAR-T cells, etc.